The Motley Fool

2 turnaround stocks that could make you rich

Circassia Pharmaceuticals (LSE: CIR) announced its half-year results this morning, offering up a significant narrowing of losses after switching its primary focus from allergies to respiratory disease. The company revealed that for the six months to 30 June, revenues had increased by 65% to £18.3m, with losses shrinking to just £34.3m from £101.8m a year earlier.

A new lease of life

The Oxford-based speciality pharmaceuticals business sells its novel, market-leading NIOX asthma management products directly to specialists in the UK, US, and Germany, and in a wide range of other countries through its network of partners. The company has also recently established a promising collaboration with AstraZeneca in the US in which it promotes the chronic obstructive pulmonary disease (COPD) treatment Tudorza, and has the US commercial rights to late-stage COPD product Duaklir.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

Throughout 2017, Circassia has continued to build on the changes it began last year following the disappointing phase III results for its lead allergy product. Since then, the company has halted investment in the allergy field, significantly expanded its commercialisation platform, and completed a major commercial transaction with AstraZeneca. With a period of dramatic change behind it, Circassia now has a strong commercial infrastructure, growing revenues, advancing pipeline and a robust balance sheet.

All of which is good news. But the company’s shares have yet to recover from last year’s disappointing clinical trials. However, I have hope for the future. The change in focus and partnership with AstraZeneca makes me optimistic that this new lease of life can transform Circassia into a profitable business, and propel the share price back to where it truly belongs.

Poised for a comeback

Despite Circassia’s long-term potential, risk-averse investors may nevertheless steer well clear of what is essentially a small-cap pharmaceuticals business that has yet to prove it can turn a profit. Such investments are not exactly the bedrock of a solid retirement portfolio.

Perhaps a more comfortable option for growth-focused investors would be Hikma Pharmaceuticals (LSE: HIK).

But Hikma has had its challenges. The FTSE 250 firm’s share price has been knocked back in recent months with investors concerned about the intense levels of competition for generic drugs in the US. The impact has been dramatic, with  the shares now trading a whopping 57% lower than last summer’s peak of 2,676p.

Poised for a comeback?

Yet Hikma is much more than just a generic drugs firm, with its injectable and branded drugs businesses contributing 65% to overall group revenues during the first half of 2017. Geographical diversity should also help to offset fierce competition in the US. The group is a market leader in the Middle East and North Africa region, as well as having significant sales in Europe and the rest of the world. This geographical diversity should help to counter the effects of tougher competition across the pond.

With an uncharacteristically low price-to-earnings ratio of 15, I believe Hikma’s shares could be well-poised for a dramatic comeback.

“This Stock Could Be Like Buying Amazon in 1997”

I'm sure you'll agree that's quite the statement from Motley Fool Co-Founder Tom Gardner.

But since our US analyst team first recommended shares in this unique tech stock back in 2016, the value has soared.

What's more, we firmly believe there's still plenty of upside in its future. In fact, even throughout the current coronavirus crisis, its performance has been beating Wall St expectations.

And right now, we're giving you a chance to discover exactly what has got our analysts all fired up about this niche industry phenomenon, in our FREE special report, A Top US Share From The Motley Fool.

Click here to claim your copy now — and we’ll tell you the name of this Top US Share… free of charge!

Bilaal Mohamed has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca and Hikma Pharmaceuticals. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

The renowned analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply enter your email address below to discover how you can take advantage of this.

I would like to receive emails from you about product information and offers from The Fool and its business partners. Each of these emails will provide a link to unsubscribe from future emails. More information about how The Fool collects, stores, and handles personal data is available in its Privacy Statement.